
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CLINICAL TRIAL article
Front. Pharmacol.
Sec. Translational Pharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1512857
The final, formatted version of the article will be published soon.
You have multiple emails registered with Frontiers:
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background:This study aimed to assess how a high-fat diet impacts the pharmacokinetics and safety characteristics of 8 mg Ondansetron hydrochloride tablets among healthy Chinese individuals.The findings presented here were obtained from a bioequivalence study, in which individuals were randomly assigned to consume Ondansetron hydrochloride tablets either following a meal or subsequent to a high-fat diet containing 978.6 kcal, with 54.6% of the calories derived from fat. The plasma concentrations of Ondansetron were measured through the utilization of high-performance liquid chromatography-mass spectrometry(LC-MS/MS) after collecting blood samples.For the computation of pharmacokinetic parameters, the non-compartmental module from Phoenix WinNonlin Version 8.2 was utilized Additionally, the BE module within WinNonLin was utilized to statistically analyze key pharmacokinetic metrics, including the maximum level of concentration (Cmax), the area beneath the concentration-time curve spanning from zero to the final quantifiable time point (AUC0-t), and the area beneath the concentration-time curve extending from zero to a theoretical limitless point (AUC0-∞) in plasma.A total of 53 healthy subjects participated in the study and were divided into a fasted cohort and a postprandial cohort.Results: Ondansetron had lower Cmax, AUC0 -t, and AUC0-∞in plasma when taken with food compared to when taken on an empty stomach, with the 90% confidence interval falling outside the acceptable range of 80.00-125.00%.The occurrence of treatment-related side effects was comparable in both the fasted and postprandial groups, as was the incidence of adverse drug reactions.The study concluded that the high-fat meal had a notable impact on how Ondansetron is processed in the body.Healthy subjects tolerated all treatments well and safely under both postprandial and fasted conditions. Clinical trial registration: [http://www.chinadrugtrials.org.cn/index.html], identifier [CTR20213116].
Keywords: Food, high-fat diet, Ondansetron, Safety, pharmacokinetics
Received: 17 Oct 2024; Accepted: 04 Mar 2025.
Copyright: © 2025 Zhao, Jia, Hu, Sun, Song, Qiu, Bai and Dong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Wanjun Bai, Hebei Key Laboratory of Clinical Pharmacy, Department of Pharmacy,Hebei General Hospita, Shijiazhuang, China
Zhanjun Dong, Hebei Key Laboratory of Clinical Pharmacy, Department of Pharmacy,Hebei General Hospita, Shijiazhuang, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.